Meta Information

ID:serms

Name:Selective Estrogen Receptor Modulators

Schema Version:1.5

Alternate Names

• SERMs

Active Compound

null

Intervention Type

therapeutic_agent

Delivery

Route:

oral

Scope:

• systemic

Regulatory Status

• us:rx_drug
• eu:rx_drug

Indication

Focus:

disease_treatment

Description:

Primarily used for the prevention and treatment of hormone receptor-positive breast cancer and osteoporosis in postmenopausal women.

Typical Protocol

• Raloxifene is typically prescribed at 60 mg daily for osteoporosis prevention or treatment.
• Tamoxifen is often prescribed at 20 mg daily for breast cancer treatment or risk reduction.

Expected Cost Mean

Low Cost:

10

High Cost:

150

Cost Type:

monthly

Description:

Generic versions are often inexpensive; typically covered by insurance for approved indications.

Summary

Selective Estrogen Receptor Modulators (SERMs) are compounds that bind to estrogen receptors, acting as either estrogen agonists (activators) or antagonists (blockers) depending on the tissue type. This tissue-selective action allows them to provide estrogen-like benefits in some tissues (e.g., bone) while blocking estrogen's effects in others (e.g., breast), making them crucial for treating specific hormone-sensitive conditions.

Purpose

Tissue-selectively mimics or blocks estrogen to treat specific hormone-related diseases.

Card Summary

A class of drugs that selectively activate or block estrogen receptors in different tissues, primarily used to treat and prevent breast cancer and osteoporosis.

Drug Class

Drugs In Class

• tamoxifen
• raloxifene
• toremifene
• bazedoxifene

Impact

Score:

8.5

Justification:

Foundational, first-line therapy for specific hormone-sensitive cancers and osteoporosis.

Evidence

Grade:

A

Score:

9.5

Justification:

Extensive, multi-decade human RCTs and meta-analyses for approved clinical indications.

Safety

Score:

6.5

Justification:

Significant risks including thromboembolic events (blood clots), stroke, and endometrial cancer.

Flags

• Increased risk of deep vein thrombosis (DVT), pulmonary embolism, and stroke.
• Tamoxifen use is associated with an increased risk of uterine cancer.
• Common side effects include hot flashes, vaginal dryness, and leg cramps.
• Contraindicated during pregnancy and breastfeeding.
• Requires careful medical supervision and regular monitoring for adverse effects.

Verdict

Essential for specific diseases; not a general healthspan or anti-aging intervention.

Created

2026-05-05T22:01:58.093957Z

Ai Model

Gemini 2.5 Pro (High)